论文部分内容阅读
目的评估细胞因子诱导的杀伤细胞(CIK 细胞)治疗晚期肝癌临床疗效.方法参照美国斯坦福大学骨髓移植中心建立的 CIK 细胞培养方法诱导扩增 CIK 细胞.培养14天后分次回输给患者,观察患者治疗前后肿瘤标志物变化、临床症状改善、生活质量、卡氏评分等,同时记录生存期.结果在46例接受CIK细胞治疗的晚期肝癌患者中临床症状治疗前、后有明显改善(P<0.05);生存质量卡氏评分提高率为73.91%;肿瘤标志物CA199有明显统计学意义(t=4.629,P <0.05); AFP有明显统计学意义(t=18.21 P<0.05).结论 CIK细胞对为那些无手术无适应症的晚期肝癌患者提供了一种继续延长生存,提高生活质量的新的途径.回输过程中做好心理护理、胃肠道反应及其他副反应的观察护理,可保证整个疗程的顺利进行.“,”Objective: To estimate the clinical effects on patients with liver cancer by cytokine-induced kiler cels (CIK). Methods: CIK cels were induced by culturing PBMC of healthy people by incubation in vitro with IL-2、γ-IFN、anti-CD3monoclonal antibody and IL-1 , then were transfused back to the patients with liver cancer after two weeks, for observation the changes of tumor weight, life quality,immunity indexes,tumor markers,(TM) and the Karnofsky’s grade. Results: Al the patients had no apparent side effect. The CA199 and the AFP from patients with liver cancer after transfused are significantly lower than that before transfused(CA199:t=4.629, P<0.05; AFP: t=18.21,P<0.05), Conclusion: CIK cels therapy enhance effect of the anti-cancer, improve survival quantity and prolong survival period., which probably provide a potent immune therapeutic strategy for patients with liver cancer. psychological care, gastrointestinal reactions and other side effects observed care in the reinfusion can ensure the smooth progress of the entire course of treatment.